Nuvectis Pharma (NVCT) Stock Price, News & Analysis

Company Overview

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Key Stats

• Today's Range: $7.42 to $7.89
• 50-Day Range: $4.52 to $7.85
• 52-Week Range: $4.44 to $12.10
• Volume: 91,653 shs
• Average Volume: 133,256 shs
• Market Capitalization: $146.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

Nuvectis Pharma Stock Analysis - MarketRank™

Nuvectis Pharma scored higher than 48% of companies evaluated by MarketBeat, and ranked 585th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nuvectis Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nuvectis Pharma are expected to grow in the coming year, from ($1.01) to ($0.95) per share.

Price to Book Value per Share Ratio

Nuvectis Pharma has a P/B Ratio of 10.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.87% of the float of Nuvectis Pharma has been sold short.

Short Interest Ratio / Days to Cover

Nuvectis Pharma has a short interest ratio ("days to cover") of 9.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvectis Pharma does not currently pay a dividend.

Dividend Growth

Nuvectis Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.87% of the float of Nuvectis Pharma has been sold short.

Short Interest Ratio / Days to Cover

Nuvectis Pharma has a short interest ratio ("days to cover") of 9.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for NVCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,300,825.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

35.78% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NVCT Stock Analysis - Frequently Asked Questions

How have NVCT shares performed this year?

Nuvectis Pharma's stock was trading at $5.41 at the start of the year. Since then, NVCT shares have increased by 40.3% and is now trading at $7.59.
View the best growth stocks for 2025 here.

How were Nuvectis Pharma's earnings last quarter?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) released its earnings results on Tuesday, November, 5th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01.

When did Nuvectis Pharma IPO?

Nuvectis Pharma (NVCT) raised $19 million in an initial public offering on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share.

Who are Nuvectis Pharma's major shareholders?

Top institutional investors of Nuvectis Pharma include Baldwin Wealth Partners LLC MA (1.84%), Marshall Wace LLP (0.64%), Forbes J M & Co. LLP (0.31%) and Millennium Management LLC (0.15%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu, Shay Shemesh and Kenneth Hoberman.
View institutional ownership trends.

How do I buy shares of Nuvectis Pharma?

Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nuvectis Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvectis Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 3/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NVCT
• CUSIP: N/A
• CIK: 1875558
• Web: www.nuvectis.com
• Phone: 201-614-3150
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +176.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,260,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -155.80%
• Return on Assets: -104.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.74
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.70 per share
• Price / Book: 10.84

Miscellaneous

• Outstanding Shares: 19,320,000
• Free Float: 12,408,000
• Market Cap: $146.64 million
• Optionable: Not Optionable
• Beta: 0.22